Jyong Biotech Ltd. (NASDAQ:MENS) Sees Large Decrease in Short Interest

Jyong Biotech Ltd. (NASDAQ:MENS) was the target of a large drop in short interest in February. As of February 27th, there was short interest totaling 373,692 shares, a drop of 19.5% from the February 12th total of 464,337 shares. Currently, 0.5% of the company’s stock are short sold. Based on an average daily volume of 422,857 shares, the days-to-cover ratio is presently 0.9 days. Based on an average daily volume of 422,857 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.5% of the company’s stock are short sold.

Jyong Biotech Trading Down 7.9%

Shares of Jyong Biotech stock traded down $0.17 during trading on Friday, hitting $1.98. 307,226 shares of the company’s stock traded hands, compared to its average volume of 329,480. Jyong Biotech has a 1 year low of $1.43 and a 1 year high of $67.00. The business has a 50-day simple moving average of $2.55 and a 200-day simple moving average of $26.74.

Jyong Biotech (NASDAQ:MENS) last posted its earnings results on Friday, January 9th. The company reported ($0.01) earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jyong Biotech in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Institutional Investors Weigh In On Jyong Biotech

A number of hedge funds have recently added to or reduced their stakes in MENS. BNP Paribas Financial Markets purchased a new stake in Jyong Biotech during the third quarter valued at $67,000. Geode Capital Management LLC boosted its position in Jyong Biotech by 19.6% in the fourth quarter. Geode Capital Management LLC now owns 64,382 shares of the company’s stock worth $254,000 after purchasing an additional 10,538 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Jyong Biotech during the 4th quarter valued at about $49,000. Millennium Management LLC bought a new position in shares of Jyong Biotech in the 3rd quarter worth approximately $512,000. Finally, Man Group plc bought a new stake in Jyong Biotech during the fourth quarter valued at approximately $56,000.

About Jyong Biotech

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.